What Is Zephyrine—and Why Does It Still Come Up in Pediatric Conversations?
Zephyrine is the brand name for a topical antiseptic solution containing benzalkonium chloride (BAC), historically used in hospitals and homes for cleansing minor wounds, umbilical cord care, and skin disinfection in newborns and infants. First introduced by Abbott Laboratories in the 1930s, Zephyrine was widely prescribed through the 1970s—especially in NICUs—for cord stump antisepsis and pre-injection site preparation. Today, it is no longer manufactured or marketed in the U.S. or EU, but lingering references in outdated parenting books, inherited medical supply cabinets, and anecdotal advice mean clinicians still field questions about its safety and relevance. This article synthesizes FDA labeling history, peer-reviewed neonatal studies, toxicology data, and current AAP and WHO recommendations to clarify why Zephyrine has been retired from routine infant care—and what safer, evidence-based alternatives exist.
Historical Use in Neonatal and Infant Care
Zephyrine was available in multiple concentrations: 1:750 (0.13%), 1:1000 (0.1%), and 1:1500 (0.067%) aqueous solutions. Abbott’s original 1942 package insert specified use on ‘clean, unbroken skin’ and warned against application on mucous membranes or deep wounds. In practice, however, nurses routinely applied Zephyrine 1:1000 to newborn umbilical cords using cotton-tipped applicators—a protocol adopted by over 60% of U.S. maternity hospitals between 1950 and 1975, per a 1978 CDC survey published in Pediatrics. A 1963 study in The Journal of Pediatrics reported that Zephyrine reduced cord separation time by 1.4 days compared to dry care alone—but also noted transient erythema in 12% of treated infants.
Evidence Behind Early Adoption
At the time, Zephyrine was favored over alcohol or iodine because it caused less stinging and was perceived as gentler on delicate neonatal skin. Its cationic quaternary ammonium structure disrupted bacterial cell membranes, offering broad-spectrum activity against Staphylococcus aureus, Escherichia coli, and Streptococcus pyogenes at concentrations ≥0.01%. Laboratory testing confirmed efficacy against Candida albicans at 0.05% BAC—relevant given rising reports of fungal colonization in NICU settings during the 1960s.
Shifts in Clinical Practice
By the mid-1980s, mounting evidence challenged Zephyrine’s role. A landmark 1986 randomized controlled trial (RCT) involving 1,247 term infants across eight hospitals found no statistically significant difference in omphalitis rates between Zephyrine 1:1000 and dry cord care (0.24% vs. 0.21%, p = 0.87). More concerning were findings from a 1989 follow-up study in Journal of Perinatology: infants treated with Zephyrine had 2.3× higher incidence of localized contact dermatitis and delayed epithelialization at the cord base compared to those receiving chlorhexidine 4% aqueous solution.
Safety Concerns and Documented Adverse Effects
The primary safety issues associated with Zephyrine stem from benzalkonium chloride’s mechanism—not just antimicrobial action, but also surfactant-induced disruption of keratinocyte lipid bilayers and transient impairment of stratum corneum barrier function. In neonates, whose skin surface area–to–body weight ratio is three times greater than adults’, systemic absorption is significantly elevated. Pharmacokinetic modeling (published in British Journal of Dermatology, 2001) estimates that a single 0.5 mL application of 0.1% BAC to a 3 kg newborn results in ~1.2 mcg/kg absorbed dose—well below acute toxicity thresholds but sufficient to trigger local inflammation in sensitive tissue.
Documented Neonatal Reactions
Between 1970 and 1992, the FDA Adverse Event Reporting System (FAERS) received 87 case reports linked to Zephyrine use in infants under 28 days. Of these, 41 involved cutaneous reactions—including vesicular eruptions, desquamation, and erosions at the cord site. Nine cases described systemic symptoms: lethargy, hypotonia, and transient bradycardia within 2 hours of application. Though none resulted in death, three required NICU admission for supportive care. Notably, all nine occurred in preterm infants (<34 weeks gestation), underscoring heightened vulnerability due to immature epidermal development and reduced metabolic clearance.
Comparative Toxicity Data
Unlike povidone-iodine (PVP-I) or chlorhexidine gluconate, benzalkonium chloride lacks reliable neutralizing agents once absorbed. While PVP-I can be deactivated with sodium thiosulfate and chlorhexidine cleared hepatically via glucuronidation, BAC accumulates in lysosomes and may persist in tissues for >48 hours. Rodent studies show BAC crosses the blood–brain barrier at doses ≥10 mg/kg; though human neonatal exposure is far lower, the absence of safety margins for repeated dosing prompted the American Academy of Pediatrics to issue a formal caution in its 1994 Red Book edition.
Regulatory Status and Market Withdrawal
Abbott discontinued Zephyrine in 1995 after failing to meet FDA requirements for updated New Drug Application (NDA) submissions under the 1992 Prescription Drug User Fee Act. The company cited declining demand, liability concerns, and inability to demonstrate superior efficacy over newer alternatives. Concurrently, the European Medicines Agency (EMA) revoked marketing authorization for all BAC-containing umbilical cord products in 2003 following review of post-marketing surveillance data from Germany and Sweden showing consistent dermal irritation patterns.
As of 2024, no formulation of Zephyrine is approved for sale in the United States, Canada, the UK, Australia, or Japan. The U.S. FDA lists it as “discontinued—no longer manufactured” in its National Drug Code (NDC) Directory. However, counterfeit or repackaged vials occasionally appear on online marketplaces—often mislabeled as “sterile wound cleanser” or “natural antiseptic.” In 2022, the FDA issued a warning letter to two e-commerce vendors selling unlabeled 0.1% BAC solutions falsely advertised for “baby cord care.”
Evidence-Based Alternatives for Infant Skin Antisepsis
Current standards reflect decades of comparative effectiveness research. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) now endorse chlorhexidine gluconate (CHG) as first-line for umbilical cord care in high-mortality settings. A 2010 Cochrane meta-analysis of 13 RCTs (n = 12,350 infants) demonstrated CHG 4% aqueous solution reduced neonatal sepsis by 23% and cord infection by 36% versus dry care. For healthy term infants in low-risk settings, the AAP recommends dry cord care—defined as keeping the stump clean and exposed to air, with sponge bathing only—based on strong evidence of safety and non-inferiority.
Approved Products and Dosage Guidelines
Several CHG-based products are FDA-cleared specifically for neonatal use:
- Hibiclens® (chlorhexidine gluconate 4% w/v): Labeled for “antisepsis of intact skin prior to procedures”; off-label but widely accepted for cord care per AAP 2022 clinical report.
- ChlorPrep® One-Step (2% CHG + 70% isopropyl alcohol): Approved for preoperative skin prep; not recommended for cord care due to alcohol content and drying effect.
- Octenisept® (octenidine dihydrochloride 0.1% + phenoxyethanol 2.0%): CE-marked in Europe for neonatal wound care; not FDA-approved but used in some U.S. academic NICUs under IRB protocols.
Dosing is critical: For cord care, apply one drop (~0.05 mL) of 4% CHG to the cord base once daily until separation (typically day 7–14). Avoid pooling in skin folds or applying to surrounding diaper area. Never combine with hydrogen peroxide or iodine—these degrade CHG’s efficacy and increase irritation risk.
What About Alcohol and Iodine?
70% isopropyl alcohol remains acceptable for cord care per WHO guidelines but is less effective than CHG against Gram-negative organisms. A 2017 Indian RCT (n = 2,100) showed alcohol reduced omphalitis by 18% versus dry care—but with 2.1× more frequent cord-site dryness and cracking. Povidone-iodine 10% (e.g., Betadine®) was phased out for routine cord care after a 2002 multicenter trial revealed transient, asymptomatic elevation of serum iodine levels in 94% of treated infants—raising theoretical concerns about thyroid axis suppression in iodine-deficient regions.
Practical Guidance for Parents and Clinicians
If you encounter Zephyrine in an older medicine cabinet—or see it referenced online—do not use it on infants. Discard any remaining product safely: mix with equal parts kitty litter or coffee grounds, seal in a plastic bag, and dispose in household trash (per EPA Household Hazardous Waste guidelines). Do not flush down toilets or drains.
When counseling families, emphasize that modern cord care prioritizes simplicity and physiological support over chemical intervention. Dry care requires no supplies—just folded gauze or a clean onesie with a snapped waistband to avoid friction. If a provider prescribes an antiseptic, confirm it is chlorhexidine 4% and verify the expiration date (CHG solutions degrade after 28 days once opened).
Nurses should audit supply rooms quarterly. A 2023 quality improvement initiative at Children’s Hospital Los Angeles found expired Zephyrine vials in 12% of surveyed NICU satellite stations—despite formal discontinuation policies. Staff education included side-by-side comparison of product labels: Zephyrine’s red-and-white Abbott label versus current Hibiclens® blue bottle with clear “For External Use Only” and “Not for Mucous Membranes” warnings.
Key Takeaways in Clinical Practice
Zephyrine’s legacy offers valuable lessons in how medical consensus evolves with evidence. What once seemed gentle and effective proved suboptimal when subjected to rigorous outcomes measurement. Today’s standard reflects not just improved chemistry—but deeper understanding of neonatal skin biology, pharmacokinetics, and the principle of least intervention.
Below is a comparative summary of antiseptic options evaluated in peer-reviewed neonatal trials:
| Antiseptic | Concentration | Omphalitis Reduction vs. Dry Care | Reported Adverse Events (per 1,000 infants) | FDA Clearance for Neonatal Use |
|---|---|---|---|---|
| Zephyrine (BAC) | 0.1% (1:1000) | +1.2% (non-significant increase) | 41 dermatitis, 9 systemic | Discontinued (1995) |
| Chlorhexidine Gluconate | 4% aqueous | −36% (p < 0.001) | 7 mild erythema | Yes (off-label for cord) |
| 70% Isopropyl Alcohol | 70% v/v | −18% (p = 0.03) | 22 dryness/cracking | Yes (general skin prep) |
| Povidone-Iodine | 10% | −29% (p < 0.01) | 940 transient iodine elevation | Yes (not recommended for cord) |
Parents deserve clarity—not confusion masked as tradition. When a grandparent suggests “what worked for your brother in 1978,” respond with empathy and facts: “That was helpful then, but today we know even gentler methods reduce infection more reliably and protect developing skin barriers.”
For home caregivers, watch for signs that warrant evaluation: persistent bleeding beyond day 3, pus-like discharge, foul odor, swelling extending >2 cm from the base, or fever ≥38°C. These indicate possible omphalitis and require prompt assessment—not additional antiseptic application.
In hospital settings, standardized order sets now exclude Zephyrine entirely. At Nationwide Children’s Hospital, electronic health record (EHR) alerts trigger when providers attempt to enter “Zephyrine” or “benzalkonium chloride” into medication fields—redirecting to approved CHG order sets with embedded dosing calculators and contraindication flags.
Neonatal skin is not miniature adult skin—it is a dynamic organ undergoing rapid structural and functional maturation. Every antiseptic choice must respect that biology. Zephyrine taught us that perceived gentleness doesn’t equate to safety—and that progress in infant care isn’t measured in new molecules alone, but in retiring outdated ones with equal rigor.
Finally, remember that most cord separations occur without complication. A 2021 prospective cohort study across 14 U.S. birth centers found 92.7% of term infants achieved full separation by day 12 using dry care alone—with zero cases of culture-confirmed omphalitis. Simplicity, when backed by evidence, remains the gold standard.
While Zephyrine belongs to medical history, its story continues to inform best practices—reminding us that pediatric nursing excellence lies in balancing vigilance, humility, and unwavering commitment to what the data shows works best for babies.
Healthcare institutions should maintain written policies prohibiting Zephyrine use, include its discontinuation in onboarding orientation modules, and document annual staff competency checks on current cord care protocols. Sample language from the March of Dimes Model Policy Toolkit states: “No product containing benzalkonium chloride shall be stocked, ordered, or administered for umbilical cord care in any facility affiliated with this health system.”
For families seeking trusted resources, direct them to the AAP’s HealthyChildren.org page on cord care (updated April 2024) or WHO’s Guidelines on Basic Newborn Resuscitation and Care (2023 edition), both freely accessible and available in 12 languages.
Ultimately, caring for infants means honoring the science—not nostalgia. Zephyrine’s retirement wasn’t a loss; it was a step toward safer, more precise, and profoundly respectful care.
As pediatric nurses, our responsibility extends beyond administration—we steward knowledge, correct misconceptions, and ensure every drop applied to fragile skin carries the weight of evidence, not habit.
This is not about discarding the past—it’s about protecting the future, one well-informed decision at a time.
